1-5 of 5
Martin Dunbar, DRPH, MS
Close
Sort by
Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, MBBS, MHS, Daniel A Pollyea, MD, Jacqueline S Garcia, MD, Andrew Brunner, MD, Fernando Roncolato, BMed, FRACP, FRCPA, Uma Borate, MD, Olatoyosi Odenike, MD, Ashish R. Bajel, FRACP, Anne Marie Watson, FRACP, FRCPA, MBBS, Katharina Götze, Florian Nolte, MD, Peter T. Tan, MBBS, Wan-Jen Hong, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Lori Gressick, BS, William Ainsworth, PhD, Jason Harb, PhD, Ahmed Hamed Salem, PhD FCP, John Hayslip, Ronan Swords, MD PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 565.
https://doi.org/10.1182/blood-2019-124994
Published: 2019
Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 568.
https://doi.org/10.1182/blood-2019-124437
Published: 2019
Journal Articles

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Andrew Wei, MBBS, PhD FRACP, FRCPA, Stephen A. Strickland, MD MSCI, Gail J. Roboz, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L. Lin, MD, Roland B. Walter, MD PhD, Anoop Enjeti, MD MRCP, FRCPA, MClin Epid, GradCert Bioethics, Brenda Chyla, PhD, Relja Popovic, PhD, Kaffa Fakouhi, Pooja Shah, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, John Hayslip, MD MSCR
Journal: Blood
Blood (2017) 130 (Supplement 1): 890.
https://doi.org/10.1182/blood.V130.Suppl_1.890.890
Published: 2017
Journal Articles

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina J. Gasparetto, MD, Joseph Mikhael, MD, Philippe Moreau, MDPhD, Cyrille Touzeau, MD PhD, Ravi Vij, MDMBA, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Martin Dunbar, DRPH, MS, Jia Jia, PhD MBA, Kevin J. Freise, PhD, Maria Verdugo, MD, Jeremy Ross, PhD MBA, Paulo Maciag, MD PhD, Shaji K Kumar, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3131.
https://doi.org/10.1182/blood.V130.Suppl_1.3131.3131
Published: 2017
Journal Articles

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

Courtney D. DiNardo, MDMSc, Daniel A. Pollyea, MD, Brian A Jonas, MD PhD, Marina Konopleva, MD PhD, Vinod Pullarkat, MD MRCP, Andrew Wei, MBBS, PhD FRACP, FRCPA, Hagop M. Kantarjian, MD, Arnaud Pigneux, MD PhD, Christian Recher, MD PhD, John F Seymour, MB BS PhDFRACP, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Keith Pratz, MD, Anthony Letai, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2628.
https://doi.org/10.1182/blood.V130.Suppl_1.2628.2628
Published: 2017